(redirected from Coreg CR)
Also found in: Thesaurus, Medical.


 (kär-vā′dĭ-lôl′, -lōl′ -vĕd′ĭ-)
A beta-blocker drug, C24H26N2O4, used especially to treat congestive heart failure and hypertension.

[carve-, probably alteration of carba(zole), one of its constituents (carb(o)- + -azole) + (vaso)dil(ator) + -ol.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.carvedilol - beta blocker that can reduce the progression of heart failure in individuals whose disease is not advanced
beta blocker, beta-adrenergic blocker, beta-adrenergic blocking agent, beta-blocking agent - any of various drugs used in treating hypertension or arrhythmia; decreases force and rate of heart contractions by blocking beta-adrenergic receptors of the autonomic nervous system
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.


n carvedilol m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
M2 EQUITYBITES-December 11, 2017-Impax wins US FDA tentative approval for generic Coreg CR ER capsules
M2 PHARMA-December 11, 2017-Impax wins US FDA tentative approval for generic Coreg CR ER capsules
IPC's lead product candidates include Dexmethylphenidate XR, a generic version of the marketed drug Focalin XR, which is partnered with Par Pharmaceutical and is currently the subject of an Abbreviated New Drug application (ANDA) filing with the United States Food and Drug Administration (FDA), and Carvedilol CR, a generic version of the brand name drug Coreg CR, an internal pipeline product now ready for entry into pivotal bioequivalence studies.
GSK and Flamel Technologies have announced FDA approval of once-a-day Coreg CR (carvedilol phosphate) extended-release capsules, for the treatment of three cardiovascular conditions:
GlaxoSmithKline, which is developing carvedilol CR (Coreg CR), submitted a New Drug Application to the Food and Drug Administration last December to have carvedilol CR approved as a treatment for hypertension.